Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to the HOVON 65/GMMG-HD4 study.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2011
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 07 Jul 2011 New source identified and integrated (Netherlands Trial Register).
- 07 Jul 2011 Additional lead trial center identified as reported by Netherlands Trial Register.
- 07 Jul 2011 Planned end date changed from 7 Feb 2010 to 1 Apr 2010 as reported by Netherlands Trial Register.